bioMérieux: Invest Securities reiterates buy rating
(CercleFinance.com) - Despite lowering its target price for bioMérieux from E111 to E104 (cp: E87, +0.
5%) Invest Securities reiterates its "buy" rating on it, believing that the in-vitro diagnostics group has once again demonstrated its resilience, with robust growth in Q3.
Noting that its historical levers are not weakening, and that new growth sources are off to a promising start, the broker still expects the top end of the target growth range and the middle of its EBITA range.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
5%) Invest Securities reiterates its "buy" rating on it, believing that the in-vitro diagnostics group has once again demonstrated its resilience, with robust growth in Q3.
Noting that its historical levers are not weakening, and that new growth sources are off to a promising start, the broker still expects the top end of the target growth range and the middle of its EBITA range.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.